Core Insights - Opus Genetics, Inc. announced that three abstracts on its investigational gene therapy candidates have been accepted for presentation at the ARVO 2025 Meeting, showcasing 12-month data from the first three adult patients in the ongoing Phase 1/2 trial of OPGx-LCA5 [1][3] - The company aims to advance OPGx-LCA5 into a pivotal Phase 3 trial, contingent on continued safety and efficacy results [3] Group 1: OPGx-LCA5 Trial Results - The ongoing Phase 1/2 trial of OPGx-LCA5 has shown that subjective and objective signs of efficacy persisted for one year in the first three adult patients [1][4] - Previous results indicated that OPGx-LCA5 was well tolerated, with all three adult patients demonstrating visual improvement at six months [4] Group 2: Upcoming Presentations - The abstracts accepted for presentation include details on OPGx-LCA5, OPGx-MERTK, and OPGx-RDH12, with specific presentation times and authors listed [2][4][5] - A subset analysis from the completed LYNX-1 Phase 3 trial of Phentolamine Ophthalmic Solution 0.75% will also be presented, focusing on reduced mesopic low contrast vision in post-LASIK subjects [6] Group 3: Company Overview - Opus Genetics is a clinical-stage ophthalmic biotechnology company focused on developing gene therapies for inherited retinal diseases and other ophthalmic disorders [7] - The company's pipeline includes several investigational gene therapies targeting various genetic mutations associated with retinal diseases, with OPGx-LCA5 being the most advanced candidate [7]
Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting